187 related articles for article (PubMed ID: 2401166)
61. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
Wang J; Lü S; Yang J; Song X; Chen L; Huang C; Hou J; Zhang W
J Hematol Oncol; 2009 Jul; 2():32. PubMed ID: 19642997
[TBL] [Abstract][Full Text] [Related]
62. Response of therapy-associated acute nonlymphocytic leukemia to intensive induction chemotherapy.
Duane SF; Peterson BA; Bloomfield CD; Michels SD; Hurd DD
Med Pediatr Oncol; 1985; 13(4):207-13. PubMed ID: 4010622
[TBL] [Abstract][Full Text] [Related]
63. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
Huang BT; Zeng QC; Yu J; Liu XL; Xiao Z; Zhu HQ
Med Oncol; 2012 Mar; 29(1):251-9. PubMed ID: 21258877
[TBL] [Abstract][Full Text] [Related]
64. Intensive sequential chemotherapy for children with acute myelogenous leukemia.
Grier HE; Gelber RD; Clavell LA; Camitta BM; Link MP; Garcea MJ; Weinstein HJ
Haematol Blood Transfus; 1990; 33():193-7. PubMed ID: 2182411
[No Abstract] [Full Text] [Related]
65. Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature.
Clarkson BD; Gee T; Arlin ZA; Mertelsmann R; Kempin SJ; Dinsmore RE; O'Reilly RJ; Andreeff M; Berman E; Little C
Crit Rev Oncol Hematol; 1986; 4(3):221-48. PubMed ID: 3513984
[TBL] [Abstract][Full Text] [Related]
66. [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].
Liu H; Qian WB; Mai WY; Meng HT; Tong HY; Tong Y; Mao LP; Huang J; Wang L; Jiang DZ; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):9-12. PubMed ID: 18512308
[TBL] [Abstract][Full Text] [Related]
67. Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine arabinoside, 6-thioguanine, and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; Hhlen K; Colly LP; Vossen JM
Pediatr Hematol Oncol; 1988; 5(2):93-102. PubMed ID: 3152962
[TBL] [Abstract][Full Text] [Related]
68. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia.
Cassileth PA; Harrington DP; Hines JD; Oken MM; Mazza JJ; McGlave P; Bennett JM; O'Connell MJ
J Clin Oncol; 1988 Apr; 6(4):583-7. PubMed ID: 3282032
[TBL] [Abstract][Full Text] [Related]
69. Reinduction chemotherapy for acute nonlymphocytic leukemia.
Letendre L; Kiely JM; Hoagland HC
Mayo Clin Proc; 1984 Sep; 59(9):618-21. PubMed ID: 6381915
[TBL] [Abstract][Full Text] [Related]
70. Multivariate analysis of factors associated with outcome of treatment for adults with acute myelogenous leukemia.
Schwartz RS; Mackintosh FR; Halpern J; Schrier SL; Greenberg PL
Cancer; 1984 Oct; 54(8):1672-81. PubMed ID: 6592033
[TBL] [Abstract][Full Text] [Related]
71. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Chan HS; Estrov Z; Weitzman SS; Freedman MH
J Clin Oncol; 1987 Dec; 5(12):1960-7. PubMed ID: 2445935
[TBL] [Abstract][Full Text] [Related]
72. D.A.T. (daunorubicin, cytarabine, 6-thioguanine) in acute myeloid leukaemia.
Rees JK; Hayhoe FG
Lancet; 1978 Jun; 1(8078):1360-1. PubMed ID: 78123
[No Abstract] [Full Text] [Related]
73. Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
Liu H; Zhang J; Ren S; Chen M; Liu L; Zhang H
Leuk Lymphoma; 2017 Nov; 58(11):2758-2761. PubMed ID: 28406352
[No Abstract] [Full Text] [Related]
74. Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Büchner T; Hiddemann W; Blasius S; Koch P; Maschmeyer G; Tirier C; Sodomann H; Kuse R; Thiel E; Ludwig WD
Haematol Blood Transfus; 1990; 33():261-6. PubMed ID: 2182419
[No Abstract] [Full Text] [Related]
75. Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Liang R; Chan TK; Todd D
Cancer Chemother Pharmacol; 1988; 21(1):68-70. PubMed ID: 3342467
[TBL] [Abstract][Full Text] [Related]
76. [Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia].
Liu CY; Fu R; Liu WH; Cheng YQ; Song WX; DU LJ; Ruan EB; Zhang LT; Wang XM; Liang Y; Wang GJ; Qu W; Song J; Zhang RL; Guan J; Li LJ; Song Y; Gao S; Liu H; Jiang HJ; Wang J; Zou P; Shao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1300-4. PubMed ID: 18088489
[TBL] [Abstract][Full Text] [Related]
77. Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.
Passe S; Miké V; Mertelsmann R; Gee TS; Clarkson BD
Cancer; 1982 Oct; 50(8):1462-71. PubMed ID: 7116285
[TBL] [Abstract][Full Text] [Related]
78. Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.
Björkholm M; Liliemark J; Gahrton G; Grimfors G; Gruber A; Hast R; Juliusson G; Järnmark M; Killander A; Kimby E
Eur J Haematol; 1995 Jul; 55(1):19-23. PubMed ID: 7615046
[TBL] [Abstract][Full Text] [Related]
79. Cell kinetics with in vivo bromodeoxyuridine and flow cytometry: clinical significance in acute non-lymphoblastic leukaemia.
Riccardi A; Giordano M; Danova M; Girino M; Brugnatelli S; Ucci G; Mazzini G
Eur J Cancer; 1991; 27(7):882-7. PubMed ID: 1834121
[TBL] [Abstract][Full Text] [Related]
80. High-dose retinol in children with acute myelogenous leukemia in remission.
Lie SO; Wathne KO; Petersen LB; Slørdahl SH; Norum KR
Eur J Haematol; 1988 May; 40(5):460-5. PubMed ID: 3163976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
